How will you use xanomeline-trospium (KarXT, Cobenfy) for patients with schizophrenia?  

I appreciate Dr. @Lim's response that summarizes some of the study data, but want to add a few details from my review of the available literature. I also am glad to hear about a new mechanism, even if the ultimate efficacy is thought to be due to downstream D2 blockade. However, I do not currently ...

KarXT, an investigational drug for schizophrenia developed by Karuna Therapeutics, combines xanomeline and trospium and is currently under FDA review. Unlike traditional antipsychotics that work by blocking post-synaptic dopamine receptors, xanomeline functions as an agonist at M1 and M4 receptors. ...